Doquyen Huynh, MD
Rheumatology · San Diego, CANPI 1619135241
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by AbbVie at 56.5% of the total. Reporting peaked in 2019 at $12,201 and has fallen 97.8% since, to $269 in 2024.
Across 326 payments — averaging $57.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Biogen$2K
- Amgen$1K
- UCB, Inc.$729
- GSK$659
- Johnson & Johnson$599
- plus $3K from 24 others
Across 22 payments — averaging $1456.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$24K
- Novartis$7K
- UCB SA$829
What the payments were for
- Speaking & faculty fees$9,75052%
- Travel & lodging$1,6579%
- Food & beverage$7,23939%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $10,539 |
| Biogen | 10 | $1,997 |
| Amgen(2 entities) | 65 | $1,303 |
| UCB, Inc. | 19 | $729 |
| GSK | 31 | $659 |
| Johnson & Johnson(2 entities) | 46 | $599 |
| Lilly USA, LLC | 20 | $400 |
| Janssen Scientific Affairs, LLC | 5 | $380 |
| Pfizer | 15 | $305 |
| Novartis | 14 | $292 |
| E.r. Squibb & Sons, L.L.C. | 10 | $291 |
| Bristol Myers Squibb | 8 | $133 |
| Genentech USA, Inc. | 7 | $131 |
| Sobi, Inc | 6 | $126 |
| Radius Health, Inc. | 4 | $99 |
| Medexus Pharma, Inc. | 5 | $85 |
| Boehringer Ingelheim | 3 | $78 |
| Mallinckrodt Enterprises LLC | 3 | $77 |
| Sanofi | 3 | $72 |
| Aurinia Pharma U.S., Inc. | 3 | $65 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| AstraZeneca | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $26 |
| Pacira Therapeutics, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Zyla Life Sciences, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,666 in reported general payments places this provider in the 80th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 95 | $656,969 |
| Humira(Cf) PenAdalimumab | 36 | $272,253 |
| Orencia ClickjectAbatacept | 26 | $151,680 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $132,027 |
| EnbrelEtanercept | 18 | $124,443 |
| Taltz AutoinjectorIxekizumab | 14 | $106,988 |
| SimponiGolimumab | 13 | $70,638 |
| Hydroxychloroquine Sulfate | 156 | $6,961 |
| MethotrexateMethotrexate Sodium | 101 | $3,914 |
| Celecoxib | 33 | $3,093 |
| Mycophenolate Mofetil | 13 | $1,872 |
| Prednisone | 135 | $1,519 |
| Gabapentin | 15 | $1,074 |
| Leflunomide | 22 | $1,016 |
| Colchicine | 21 | $899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $1,303 | $124,44318 claims |
| Johnson & JohnsonSimponi | $599 | $70,63813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 808 rheumatology providers in California.
Other rheumatology in San Diego
- Ara DikranianSan Diego$2.2M
- Arthur MabaquiaoSan Diego$209K
- Kenneth KalunianSan Diego$194K
- Sudhakar TumuluriSan Francisco$2.8M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.